Combined therapy of cerebrovascular disorders with neuroprotectors

Putilina M.V.

doi:https://doi.org/10.17116/jnevro201611611158-63

Close metadata

Recommended articles:

Cognitive impairment in asthenic disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):27-32

Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77

Stress and sleep: Neurobiological aspects and modern options of insomnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Early diagnosis and effective therapy of diabetic polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68

Results of the All-Russian consensus conference on complications in bariatric surgery. Endoscopic Surgery. 2025;(1):15-24

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coronary intervention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200

Influence of griseofulvin on intestinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):185-190

Postoperative peritonitis: epidemiology, diagnosis, surgical treatment and prognosis. Pirogov Russian Journal of Surgery. 2025;(6):104-111

Abstract:

Safety of drugs is one of the priorities of modern medicine. The goal of pharmacological treatment is a search for effective and safety drugs as well as a study of possibilities of combined using of the drugs with opposite effects. Basing on the possible therapeutic interactions, 2-ethyl-6-methyl-3-hydroxypyridine succinate can be recommended as a basic medication for patients with cerebrovascular diseases to normalize the energy metabolism of brain cells. The complex use of cholinergic drugs with different neuroprotective effects is effective from the first hours after admission. Cholinergic drugs (citicoline or choline alfoscerate) as the drugs of the first choice should be justified taking into consideration dysfunction of the brain system activation. Patient’s age, the level of consciousness, somatic pathology, previous strokes, cognitive impairment are predictors of treatment efficacy.

Keywords:

safety of drugs

citicoline

choline alfoscerate

2-ethyl-6-methyl-3-hydroxypyridine succinate

treatment

Authors:

Putilina M.V.

Kafedra nevrologii fakulteta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Close metadata

References:

Afanas'ev VV, Luk'yanova IYu. Side effects of drugs in their interaction. Part 2. Rules of pharmacodynamics. Skoraya meditsinskaya pomoshch'. 2004;1:8-17. (In Russ.).
Lepakhin VK, Astakhova AV, Ovchinnikova EA, Ovchinnikova LK. Medical error as a cause of complications of medicinal therapy. Kachestvennaya klinicheskaya praktika. 2002;1:71-77. (In Russ.).
Panchuk S, Yabluchanskii N. Drug safety. Medicus Amicus. 2014. (In Russ.).
Putilina MV. Risk factors, features of clinical course and treatment approaches in aged and old patients with cerebral stroke Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2011;111:110:5:90-95. (In Russ.).
Burchinskii SG. Hazards and risks of nootropic drug therapy: myth or reality? Ratsional'naya farmakoterapiya. 2007;1:62-66. (In Russ.).
Rumyantseva SA, Afanas’eva VV, Silina EV. Pathophysiological basis of the complex neuroprotection in brain Ischemia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2009;109:3:64-68. (In Russ.).
Burchinskii SG. Combined neurotropic drugs and the problem of optimization of complex pharmacotherapy in neurology. Mezhdunarodnyi nevrologicheskii zhurnal. 2006;2(6). (In Russ.).
Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv. XIII vypusk. M. 2012;303. (In Russ.).
Skvortsova VI, Stakhovskaya LV, Nartsyssov YaR, Bodykhov MK, Kichuck IV, Gudkova YuV, Soldatenkova TD, Kondrasheva TT, Kalinina EV, Novichkova MD, Kerbikov OB. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. Insul't. Tematicheskii vypusk Zhurnala nevrologii i psikhiatrii im. S.S. Korsakova. 2006;18:47-54. (In Russ.).
Parfenov VA. Otchet klinicheskogo issledovaniya effektivnosti i bezopasnosti primeneniya preparata Meksikor pri ishemicheskom insul'te. The link is active on: 12.09.16. Available at: http://www.mexicor.ru/neurology/pdf/2008_3.pdf (In Russ.).
Tanashyan MM, Lagoda OV, Fedin PA, Kshova II, Rodionova YuV. Antioxidant therapy in chronic cerebrovascular diseases. RMZh. 2010;18:6:1-4. (In Russ.).
Abramenko YuV. The assessment of the clinical efficacy, vasoactive and metabolic effects of mexidol in elderly patients with discirculatory encephalopathy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2011;111(11):35-41. (In Russ.).
Putilina MV, Gryshin DV. Mexiprim in the complex treatment of patients with cervical dorsopathy and the vertebral artery syndrome. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2011;111(11):29-34. (In Russ.).
Kutsemelov IB, Kushnareva VV, Efremov VV, Erofeeva AV. The use of modern antioxidants (mexiprim) in complex treatment of patients with chronic cerebrovascular insufficiency. RMZh. 2012;5:1-4. (In Russ.).
Voronina TA. Mexidol: main effects, mechanism of action. Farmateka. 2009;6:35-38. (In Russ.).
Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112:12:86-90. (In Russ.).
Duma SN, Ragin YuI. The role of antioxidants in correction of psychovegetative, asthenic and cognitive disorders. Trudnyi patsient. 2011;4:9:26-30. (In Russ.).
Pizova NV. Succinic acid derivatives in therapy for cerebrovascular disease. Neurology, Neuropsychiatry, Psychosomatics. 2010;2(1):67-68. (In Russ.). doi: 10.14412/2074-2711-2010-74
Mayorova NG, Pavlov VA, Mayorova NG, Pavlov VA. Clinical experience with Neurox used in patients with cerebrovascular disease. Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1):71-74. (In Russ.). doi: 10.14412/2074-2711-2011-138
Putilina MV. Combined neuroprotective therapy for cerebrovascular diseases. Vrach. 2012;4:69-74. (In Russ.).
Adibhatla RM, Hatcher JF, Larsen EC, Chen X, Sun D, Tsao FHC. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting Phospholipase A2 and CTP: phosphocholine cytidylyltransferase after Stroke. J Biol Chem. 2006;281:10:6718-6725. http://dx.doi.org/10.1074/jbc.m512112200
Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp Neurol. 2000;161:733-739. http://dx.doi.org/10.1006/exnr.1999.7314
Secades JJ. CDP-choline:update and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol. 2002;24(suppl B):1-53.
Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on cholinecontaining phospholipids. J Neural Transm. 2000;107:1027-1063. doi: 10.1007/s007020070051
Adibhatla RM, Hatcher JF. Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005;30:15-23. doi: 10.1007/s11064-004-9681-8
Alvarez XA, Sampedro C, Lozano R, Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods Find Exp Clin Pharmacol. 1999;21:535-540. http://dx.doi.org/10.1358/mf.1999.21.8.794835
Mendelevich EG. Chronic cerebral vascular insufficiency: clinical nerovisual parameters, risk factors and neuroprotective therapy. RMZh. 2016;7:424-428. (In Russ.).
Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009;5:33-38. http://dx.doi.org/10.3988/jcn.2009.5.1.33
Sobrino T, Hurtado O, Moro MA, Rodriguez-Yanez M,Castellanos M, Brea D, Moldes O, Blanco M, Arenillas JF, Leira R, Davalos A, Lizasoain I, Castillo J. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke. 2007;38:2759-2764. http://dx.doi.org/10.1161/strokeaha.107.484386
Ye J, Lin H, Mu J, Cui X, Ying H, Lin M, Wu L, Weng J, Lin X. Effect of basic fibroblast growth factor on hippocampal cholinergic neurons in a rodent model of ischaemic encephalopathy. Basic Clin Pharmacol Toxicol. 2010. http://dx.doi.org/10.1111/j.1742-7843.2010.00603.x
Lin J, Lin K, Masruha MR, Vilanova LCP. Pyridoxine — dependant epilepsy initially responsive to phenobarbital. Arq Neuro-Psyquiatr. 2007;65(4a):1026-1029. http://dx.doi.org/10.1590/s0004-282x2007000600023
Alvarez-Sabin J, Ortega G, Jacas C, Quintana M, Ribo M, Santamarina E, Maisterra O, Molina C, Montaner J, Roman G.Citicoline treatment prevents neurocognitive decline after a first ischemic stroke (Poster 743). Cerebrovasc Dis. 2010;29(suppl 2):268.
Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci. 2010;299:188-192. http://dx.doi.org/10.1016/j.jns.2010.08.027
Lopez CM, Govoni S, Battaini F, Bergamaschi S, Longoni A, Giaroni C, Trabucchi M. Effect of a new cognition enhancer, alpha-glycerylphosphorylcholine, on scopolamine-induced amnesia and brain acetylcholine. Pharmacol Biochem Behav. 1991;39:4:835-840. http://dx.doi.org/10.1016/0091-3057(91)90040-9
Vereshchagin EI. Modern possibilities of neuroprotection in acute ischemic stroke and traumatic brain injury (review). Zhurnal intensivnoi terapii. 2006;3:4-28. (In Russ.).
Belenichev IF, Chernii VI, Kolesnikov YuM. Ratsional'naya neiroprotektsiya. Donetsk: Izdatel' Zaslavskii A.Yu.; 2009. (In Russ.).
Yanishevskii SN, Odinak MM, Voznyuk IA, Onishchenko LS. Klinicheskaya i morfologicheskaya otsenka effektivnosti preparatov s metabolicheskoi aktivnost'yu pri ostroi tserebral'noi ishemii. Sovremennye podkhody k diagnostike i lecheniyu nervnykh i psikhicheskikh zabolevanii. SPb. 2000;364-365. (In Russ.).
Rumyantseva SA, Afanas'ev VV, Silina EV. Vtoroi shans. MIG. M.—SPb. 2011. (In Russ.).
Amenta F, Carotenuto A, Fasanaro AM, Lanari A, Previdi P, Rea R. Analisi comparativa della sicurezza/efficacia degli inibitori delle colinesterasi e del precursore colinergico colina alfoscerato nelle demenze ad esordio nell’eta adulta. G Gerontol. 2010;58:64-68.
Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechanisms of Ageing and Development. 2001;122:16:2041-2055. http://dx.doi.org/10.1016/s0047-6374(01)00312-8
Barbagallo SG, Barbagallo M, Giordano M, Meli M, Panzarasa R. α-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Pharmacology of Aging Process (Annals of the New York Academy of Sciences). 1994;717:253-269. http://dx.doi.org/10.1111/j.1749-6632.1994.tb12095.x
Amenta F, Franch F, Ricci A, Vega JA. Cholinergic neurotransmission in the hippocampus of aged rats: influence of L-al-pha-glycerylphosphorylcholine treatment. Ann NY Acad Sci. 1993;695:311-313. http://dx.doi.org/10.1111/j.1749-6632.1993.tb23073.x
Stulin ID, Musin RS, Solonsky DS. Choline alphoscerate (ceretone) in the treatment of patients with chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2009;109:7:87-89. (In Russ.).
Voznyuk I.A., Golokhvastov S.Yu., Fokin V.A. Violations of cerebral blood flow and perfusion disorders in the acute phase of ischemic stroke. Materialy II Rossiiskogo mezhdunarodnogo kongressa «Tserebrovaskulyarnaya patologiya i insul't». Spets. vypusk. Insul't (prilozhenie k Zhurnalu nevrologii i psikhiatrii im. S.S. Korsakova). 2007;242-243. (In Russ.).
Chernii TV. Choline alphosceratus, gliatilin — new perspectives in modern strategies of cerebral neuroprotection. Aktual'nye napravleniya v nevrologii (materialy KhІII Mezhdunarodnoi konferentsii, 27—29 aprelya 2011 goda, Sudak). Kiev. 2011;166170. (In Russ.).
Putilina M. Combined neuroprotective therapy for cerebrovascular diseases. Vrach. 2012;4:34-41. (In Russ.).
Solovieva EY, Farrahova KI, Karneev AN, Chipova DT. Phospholipids metabolism disorders in acute stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116:1:104-112. (In Russ.). doi: 10.17116/jnevro201611611104-112
Fedin AI, Eliseev EV, Rumyantseva SA, Golonzko VA. Putilina MV, Benevol'skaya NG. Experience in the treatment of acute stroke in the conditions of intensive care unit of the vascular compartment. Simple solutions to complex problems. Rossiiskii kliniko-farmatsevticheskii vestnik. 2009;1:90. (In Russ.).
Putilina MV. Risk factors, features of clinical course and treatment approaches in aged and old patients with cerebral stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2011;111:5:90-95. (In Russ.).
Afanas'ev VV. Clinical application of citicoline and its role in the homeostasis of cellular membranes of neurons and organs (effectors). Trudnyi patsient. 2009;7. (In Russ.).
Wurtman RJ. Choline metabolism as a basis for the selective wulnerability of cholinergic neurons. Trends Neurosciences. 1992;15:117-122. http://dx.doi.org/10.1016/0166-2236(92)90351-8
Li Z, Vance D. Thematic review series; glycerolipids. Phosphatidylcholine and choline homeostasis. J Lipid Res. 2008;49:6:1187-1194. doi: 10.1194/jlr.R700019-JLR200
Pizova NV. The use of cereton in patients with chronic brain ischemia and moderate cognitive impairment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014;114:12:88-93. (In Russ.).